ABUS Research and Charts

ABUS - Arbutus Biopharma Corp (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-09-15)

Last 4.53	Change ⇑ +0.07 (+1.57%)	Volume 968,003
	Open 4.50	High 4.57	Low 4.37

8EMA (Daily) 4.39	40EMA (Daily) 3.78	50EMA (Daily) 3.71	STO (Daily) 80.612	MACD Hist (Daily) 0.142
8EMA (Weekly) 3.961	40EMA (Weekly) 3.50	50EMA (Weekly) 3.46	STO (Weekly) 82.858	MACD Hist (Weekly) 0.290


Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.